TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00027560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.
Study: NCT00317512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)
Study: NCT00027560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study: NCT01159704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Education Model
Description: The peer education intervention will be delivered by trained outreach workers in a group format with 8-10 indexes over five sessions spanning three weeks. The sessions will focus on knowledge of HIV transmission, self-efficacy and skills-building regarding HIV risk reduction, with an emphasis on the dissemination of such information and skills to network members.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Counseling and Education Model
Description: The C \& E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
Study: NCT00027560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT04549467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 MG
Description: Experimental arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine / Tenofovir Disoproxil Pill
Description: Active Comparator
Study: NCT01092221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 1 capsule 300 mg, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule, 300 mg, BID
Study: NCT01447537

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + relaxation
Description: Exercise + relaxation

Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation
Description: Relaxation without exercise Patients will receive only relaxation for 3 months
Study: NCT00317512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven
Study: NCT01159704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Counseling and Education Model
Description: The C \& E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
Study: NCT03753594

Intervention type: DEVICE
Intervention: tissue oxygenation saturation
Description: tissue oxygenation saturation

Intervention type: DEVICE
Intervention: tissue oxygenation saturation
Description: tissue oxygenation saturation
Study: NCT01771588

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human milk fortifier

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk fortifier

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk fortifier
Study: NCT03615924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~* \>48 kg: Ticagrelor 45 mg, twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~* \>48 kg: Placebo to match ticagrelor 45 mg, twice a day.
Study: NCT00783354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (Placebo) in case of symptoms for 2 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (desloratadine 5 mg) in case of symptoms for 2 months.
Study: NCT03417492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Three 20 mg capsules for the single dose studies. For the 5-week treatment phase, subjects will be assigned to a titration of doses for the 5 week duration of the study. Subjects will be instructed to take 20mg twice per day for 3 days, then 40mg twice per day for 3 days, and then 80mg twice per day for 4 weeks.
Study: NCT00420654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: 1.25 mg, 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent to 1.25 mg, 6 months

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy controls
Description: Healthy controls
Study: NCT02954016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePass
Description: Subject is implanted with the device for up to 3 years.
Study: NCT00974025

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: High-dose Vitamin C will be administered in 4 age-based dosing groups

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered twice daily for four weeks
Study: NCT03778099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinnamon Cap 500 MG
Description: The Cinnamomum cassia (C. aromaticum) capsules will be purchase from Spring Valley company (distributed by Wal-Mart Stores, Inc. USA) by the investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 450 mg of starch and 50 mg of cinnamon powder
Study: NCT00568854

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
Study: NCT03085316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device
Description: Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
Study: NCT00053235

Intervention type: GENETIC
Intervention: Comparative Genomic Hybridization
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: GENETIC
Intervention: Polymerase Chain Reaction
Description: Correlative studies
Study: NCT02051426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-serine
Description: single P.O. administration of D-serine (2.1g)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single P.O. administration of Placebo
Study: NCT01471613

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Treatment
Description: Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
Study: NCT00964197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemmeJock
Description: The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
Study: NCT01471613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate Tablet
Description: 250mg/tablet, administrated orally for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate Tablet
Description: 250mg/tablet, administrated orally for 6 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood Cell
Description: Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood Cell
Description: Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, orally administration of placebo for 6 weeks
Study: NCT02962791

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization therapy implantation
Description: Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy implantation
Description: Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure
Study: NCT02170805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS powder plus solution
Description: BIBR 1048 MS, powder plus solution 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40 mg
Study: NCT02962791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation of 3 ventricular sites
Description: Cardiac resynchronization therapy with stimulation of 3 ventricular sites

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of 2 ventricular sites
Description: Cardiac resynchronization therapy with stimulation of 2 ventricular sites

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Standard Echocardiography will de bone for patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Standard Echocardiography will de bone for patient
Study: NCT00518869

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PG2
Description: 500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: 500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
Study: NCT02326649

Intervention type: DEVICE
Intervention: Physioflow
Description: impedance cardiography instrument that measures cardiac output non-invasively
Study: NCT04045106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Patterns
Description: The participants were asked to sit on a chair, the therapist performed the pattern of movement himself then passively applied the pattern on the participant then asked the participant to perform the pattern, and the therapist observed and corrected the movement if it was done improperly.Then participants were told that the therapist will resist their movement, they were also told to keep breathing normally and to report any discomfort and/or pain.After mastering the pattern,the therapist placed one hand on the participant's mandibular and the other hand approximately between parietal and occipital bones to apply resistance through out the ROM, each pattern performed for 3 sets of 10 repetitions with 1-2-minute rest between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation stretching
Description: was done for 6 repetitions with hold for 6 seconds in position of stretch and sub maximal isometric contraction for 6 seconds, 1-2-minute rest was given before changing the target muscle group

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Passive range of motion
Description: ineffective passive ROM for 10 repetitions for flexion, extension, right and left side bending and right and left rotation, it was done from neutral position to the limit of motion without causing any stretch to the muscle.
Study: NCT04554628

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ELISA test in urine
Description: enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ELISA test in urine
Description: enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
Study: NCT00777244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MITOTANE
Description: mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
Study: NCT03089840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrganOx metra
Description: Following the routine retrieval procedure at the donor hospital the liver will be flushed with cold preservation solution and prepared for cannulation. The donor organ is then placed on the OrganOx metra device and will be perfused with warmed solution. The OrganOx metra device containing the donor organ is then transported to the recipient transplant centre. The donor liver is then removed from the device and flushed with standard of care preservation solution. Alternatively, where more practical, the livers will be transported to the University of Alberta hospital with ≤ 6 hours of cold storage and then placed on the metra™ for ≥ 4 hours. Implantation and reperfusion of the liver proceed as per the usual practice of the recipient transplant centre.
Study: NCT00281489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS Monitor guided algorithm
Description: BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Volatile anesthetic guided algorithm
Description: Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
Study: NCT04297917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: chimpanzee adenovirus-vectored hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: chimpanzee adenovirus-vectored hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: chimpanzee adenovirus-vectored hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: chimpanzee adenovirus-vectored hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: chimpanzee adenovirus-vectored hepatitis B virus vaccine
Study: NCT03717493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Regulation Training
Description: Following the guidelines for the 6-week intensive ART format, we scheduled one 180-minutes session per week (each consisting of two modules à 90min) for a period of six subsequent weeks. Training groups included four to eight participants. The implementation of ART followed standardized treatment protocols (Berking \& Whitley, 2014). ART was delivered by doctoral candidates (DCs) in clinical psychology who had completed or were in advanced stages of their clinical training. All therapists had been intensely trained and received weekly supervision from experienced ART trainers. To control adherence a random sample of 5% of all sessions was be videotaped and will be rated with regard to adherence.
Study: NCT02493920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained lung inflation
Description: Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).
Study: NCT04297917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: chimpanzee adenovirus-vectored hepatitis B virus vaccine
Study: NCT03897413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-888711
Description: Administered orally as three 0.25 mg tablets
Study: NCT01930175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02592759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Glove Treatment
Description: Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
Study: NCT02291471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001，10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001，20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001，35mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001，50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001，65mg
Study: NCT03897413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-888711
Description: Administered orally as three 0.25 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-888711
Description: Administered orally as three 0.25 mg tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Antacid
Description: Calcium carbonate 4000 mg chewable tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Antacid
Description: Calcium carbonate 4000 mg chewable tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Antacid
Description: Calcium carbonate 4000 mg chewable tablets
Study: NCT01392313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnitine
Description: Carnitine Ingestion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Carnitine placebo
Study: NCT02170805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40 mg
Study: NCT01449682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex
Description: 0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex
Description: 0.7 mg intravitreal DEX implant on first visit then every 16 weeks